Home » Stocks » UMRX

Cogent Biosciences, Inc. (UMRX)

Oct 6, 2020 - Stock symbol was changed to COGT
Stock Price: $2.35 USD 0.00 (0.00%)
Updated Oct 5, 2020 4:00 PM EDT
Market Cap 99.80M
Revenue (ttm) 23.87M
Net Income (ttm) -23.11M
Shares Out 31.11M
EPS (ttm) -0.86
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day Oct 5, 2020
Last Price $2.35
Previous Close $2.35
Change ($) 0.00
Change (%) 0.00%
Day's Open -
Day's Range 2.32 - 2.41
Day's Volume 0
52-Week Range 0.30 - 3.72

News

Hide News
PRNewsWire - 3 months ago

CAMBRIDGE, Mass., Oct. 5, 2020 /PRNewswire/ -- Unum Therapeutics Inc. ("Unum") (NASDAQ: UMRX), a biotechnology company focused on developing precision therapies for genetically defined disease...

Zacks Investment Research - 3 months ago

Is (UMRX) Outperforming Other Medical Stocks This Year?

PRNewsWire - 4 months ago

CAMBRIDGE, Mass., Aug. 31, 2020 /PRNewswire/ -- Unum Therapeutics Inc.

PRNewsWire - 5 months ago

CAMBRIDGE, Mass., Aug. 11, 2020 /PRNewswire/ -- Unum Therapeutics Inc.

Zacks Investment Research - 5 months ago

On Aug 6, the Nasdaq Composite Index topped the milestone of 11,000. The tech-heavy laden completed its 1000-point journey in 40 trading days, representing the fastest ever rise in 20 years.

Other stocks mentioned: KOPN, NVAX, QDEL, VERI
Zacks Investment Research - 5 months ago

Is (UMRX) Outperforming Other Medical Stocks This Year?

Zacks Investment Research - 5 months ago

Unum Therapeutics Inc. (UMRX) closed the most recent trading day at $2.74, moving +1.86% from the previous trading session.

PRNewsWire - 5 months ago

PHILADELPHIA, July 21, 2020 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating Unum Therapeutics Inc. (NASDAQ: UMRX) ("Unum" or the "Company") on behalf of the Company's invest...

Zacks Investment Research - 5 months ago

Top Ranked Momentum Stocks to Buy for July 17th

Other stocks mentioned: MXIM, TMO
Zacks Investment Research - 6 months ago

Top Ranked Momentum Stocks to Buy for July 10th

Other stocks mentioned: BSIG, NLS, PCRX
Zacks Investment Research - 6 months ago

As of late, it has definitely been a great time to be an investor in Unum Therapeutics Inc. (UMRX).

Zacks Investment Research - 6 months ago

Unum Therapeutics (UMRX) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

InvestorPlace - 6 months ago

Unum Therapeutics (UMRX) stock is on the rise Tuesday following the acquisition of private biotechnology company Kiq on Monday. The post Unum Therapeutics: Why UMRX Stock Is Shooting 7% Higher...

PRNewsWire - 6 months ago

CAMBRIDGE, Mass. and PHILADELPHIA, July 6, 2020 /PRNewswire/ -- Unum Therapeutics Inc. ("Unum") (NASDAQ: UMRX), a biopharmaceutical company focused on developing therapies for solid tumors, to...

Zacks Investment Research - 8 months ago

Unum Therapeutics Inc (UMRX) delivered earnings and revenue surprises of 39.39% and 134.37%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for th...

Zacks Investment Research - 8 months ago

During Unum Therapeutics' (UMRX) upcoming Q1 earnings call, investor focus will be on the company's progress pertaining to its preclinical program, BOXR1030, for treating solid tumor cancers.

Zacks Investment Research - 9 months ago

Unum Therapeutics Inc. (UMRX) delivered earnings and revenue surprises of 120.00% and 271.07%, respectively, for the quarter ended December 2019.

GlobeNewsWire - 9 months ago

CAMBRIDGE, Mass., March 20, 2020 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a biopharmaceutical company focused on developing curative cell therapies for solid tumors, today ...

Zacks Investment Research - 9 months ago

Unum Therapeutics Inc. (UMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

GlobeNewsWire - 10 months ago

BOXR1030 is a GPC3-targeted CAR T cell incorporating the novel GOT2 transgene designed to improve T cell function in the solid tumor microenvironment by enhancing T cell metabolism

GlobeNewsWire - 11 months ago

-Cohort 1 enrollment is complete with no dose-limiting toxicities observed-

GlobeNewsWire - 1 year ago

-Clinical response and safety data with ACTR707 provide proof-of-mechanism for the ACTR platform and support the ongoing Phase 1 dose-escalation trial in relapsed or refractory NHL- -Clinical ...

Zacks Investment Research - 1 year ago

Unum Therapeutics Inc. (UMRX) delivered earnings and revenue surprises of -25.81% and -76.87%, respectively, for the quarter ended September 2019.

Zacks Investment Research - 1 year ago

Unum Therapeutics Inc. (UMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Zacks Investment Research - 1 year ago

Unum (UNM) delivered earnings and revenue surprises of -0.73% and -0.78%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 1 year ago

CAMBRIDGE, Mass., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on developing curative cell therapies for cancer...

Zacks Investment Research - 1 year ago

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Unum (UNM) have what it takes?

GlobeNewsWire - 1 year ago

CAMBRIDGE, Mass., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on developing curative cell therapies for cance...

Zacks Investment Research - 1 year ago

Unum (UNM) reported earnings 30 days ago. What's next for the stock?

GlobeNewsWire - 1 year ago

CAMBRIDGE, Mass., Aug. 26, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on developing curative cell therapies for cancer...

Seeking Alpha - 1 year ago

Unum Therapeutics Inc. (UMRX) CEO Chuck Wilson on Q2 2019 - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Unum Therapeutics Inc. (UMRX) delivered earnings and revenue surprises of 12.82% and 1.36%, respectively, for the quarter ended June 2019.

Seeking Alpha - 1 year ago

Unum Group (UNM) CEO Richard McKenney on Q2 2019 Results - Earnings Call Transcript

Other stocks mentioned: UNM
Zacks Investment Research - 1 year ago

Unum (UNM) delivered earnings and revenue surprises of 1.49% and 1.22%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

Unum (UNM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor in Unum Therapeutics.

Benzinga - 1 year ago

Unum Therapeutics Inc (NASDAQ: UMRX) shares were under pressure Wednesday following a clinical trial update provided by the company late Tuesday.

Market Watch - 1 year ago

Shares of Unum Therapeutics Inc. tumbled 19% toward a record low in premarket trading Wednesday, after the Food and Drug Administration placed a "clinical hold" on the phase 1 trial of its can...

Seeking Alpha - 1 year ago

Unum Therapeutics Inc.'s (UMRX) CEO Chuck Wilson on Q1 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Unum Therapeutics Inc. (UMRX) delivered earnings and revenue surprises of -25.81% and -2.96%, respectively, for the quarter ended March 2019.

Seeking Alpha - 1 year ago

Unum Therapeutics Inc.'s (UMRX) CEO Chuck Wilson on Q4 2018 Results - Earnings Call Transcript

About UMRX

Unum Therapeutics, a biopharmaceutical company, focuses on developing a pipeline of novel therapies to treat cancer patients. The company's novel proprietary technology, known as Bolt-On Chimeric Receptor (BOXR), is designed to improve the functionality of engineered T cells by discovering and incorporating a ?bolt-on' transgene into a patients' engineered T cells to overcome resistance of the solid tumor microenvironment to T cell attack. Its advanced program, PLX9486, is a selective KIT D816V inhibitor that is being developed to treat patient... [Read more...]

Industry
Biotechnology
IPO Date
Mar 29, 2018
CEO
Charles Wilson
Country
United States
Stock Exchange
NASDAQ
Ticker Symbol
UMRX
Full Company Profile

Financial Performance

In 2019, UMRX's revenue was $22.50 million, an increase of 131.14% compared to the previous year's $9.73 million. Losses were -$31.83 million, -7.82% less than in 2018.

Financial Statements